Gain Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
GANX$1.09+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Operations
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · 2023 · 2022 | ||||||
| Revenues: · · · | ||||||
| Collaboration revenues | | $55,180 | | $132,640 | ||
| Other income | | | — | | 7,468 | |
| Total revenues | | | 55,180 | | | 140,108 |
| | | | | | | |
| Operating expenses: | | | ||||
| Research and development | | (11,520,613) | | (8,377,290) | ||
| General and administrative | | (10,787,700) | | (9,539,863) | ||
| Total operating expenses | | | (22,308,313) | | | (17,917,153) |
| | | | | | | |
| Loss from operations | | | (22,253,133) | | | (17,777,045) |
| | | | | | | |
| Other income (expense): | | | ||||
| Interest income, net | | 494,234 | | 375,357 | ||
| Foreign exchange loss, net | | (429,346) | | (96,074) | ||
| Loss before income tax | | $(22,188,245) | | $(17,497,762) | ||
| | | | | | | |
| Income tax | | (79,275) | | (92,976) | ||
| | | | | | | |
| Net loss | | $(22,267,520) | | $(17,590,738) | ||
| | | | | | | |
| Net loss per shares: | | | ||||
| Net loss per share attributable to common stockholders - basic and diluted | | $(1.71) | | $(1.48) | ||
| Weighted average common stock - basic and diluted | | 13,011,361 | | 11,883,368 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.